Sale of Boston Scientific's cardiac surgery and vascular surgery units will be considered as part of the firm's ongoing effort to divest "non-strategic" assets to help cut costs and reduce debt, the company announces Aug. 16. The move comes on top of earlier plans to explore the sale of the firm's Namic fluid management business, announced July 24 (1"The Gray Sheet" July 30, 2007, p. 17), and the recent sale of its cochlear implant business (2"The Gray Sheet" Aug. 13, 2007, p. 11). Boston Scientific recently decided to retain its endosurgery and pain management businesses, however, following a review (3"The Gray Sheet" Aug. 6, 2007, In Brief). Boston Scientific acquired the cardiac surgery unit, which makes minimally invasive heart surgery devices and generates $189 million in annual sales, as part of its April 2006 acquisition of Guidant. The vascular surgery division, which makes aneurysm repair devices and generates sales of $86 million, was acquired with Meadox Medicals in 1995...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
16 June marked the first major new regulatory instrument in the UK’s post-Brexit transition to a standalone device regulatory system for Great Britain.
With a test platform designed to mirror the biological diversity of cancer, Harbinger Health is moving beyond traditional performance measures to introduce cancer-specific sensitivity and “intrinsic accuracy” as cornerstones of its clinical narrative.
Eko hopes its new partnership with Boehringer Ingelheim to develop algorithms for accurately detecting heart murmurs in dogs will pave the way for more collaborations with medical and pharmaceutical companies to advance early detection in humans as well as animals.
